Cancer drug developer Antisoma plc (LSE:ASM) announces the presentation of long-term follow-up data from the phase I trial of its aptamer drug AS1411. The new data extend results presented at the ASCO meeting in May, where promising signs of anti-cancer activity were reported in the trial’s three renal cancer patients. At that time, one of these patients had shown a near-complete response, having experienced dramatic shrinkage of a large tumour. This patient is still in remission 16 months after treatment.
